IP Library Granted Patent US 7,776,893
Granted Patent B2
US 7,776,893 · App. 10/570,622 · Granted Aug 17, 2010

Use of PDE4 inhibitors for the treatment of diabetes mellitus

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,776,893
App. No.
10/570,622
Granted
Aug 17, 2010
Kind
B2
Abstract

The invention relates to the use of certain known PIDE4 inhibitors for the treatment of diabetes mellitus and accompanying disorders thereof.

Claims (8)

1. A method for treating diabetes mellitus type 2 in a patient, comprising administering to a patient in need thereof an effective amount of N-(3,5-Dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide.

2. The method of claim 1 , wherein administering comprises administering the N-(3,5-Dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide in a dosage form selected from the group consisting of an oral dosage form; an injectable dosage form; and an infusible dosage form.

3. The method of claim 2 , wherein the dosage form comprises an oral dosage form.

4. The method of claim 2 , wherein the dosage form comprises an injectable or an infusible dosage form.

5. A method for treating diabetes mellitus type 2 in a patient, comprising administering to a patient in need thereof an effective amount of a compound selected from the group consisting of N-(3,5-Dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide; a pharmaceutically acceptable salt thereof; an N-oxide thereof; and a pharmaceutically acceptable salt of an N-oxide thereof.

6. The method of claim 5 , wherein said administering comprises administering the compound in a dosage form selected from the group consisting of an oral dosage form; an injectable dosage form; and an infusible dosage form.

7. The method of claim 6 , wherein the dosage form comprises an oral dosage form.

8. The method of claim 6 , wherein the dosage form comprises an injectable or an infusible dosage form.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2017
From: TAKEDA GMBH
To: ASTRAZENECA AB
Reel/Frame 041328/0362 →
CHANGE OF NAME Recorded Jul 29, 2015
From: NYCOMED GERMANY HOLDING GMBH
To: TAKEDA GMBH
Reel/Frame 036205/0192 →
MERGER Recorded Jul 28, 2015
From: NYCOMED ASSET MANAGEMENT GMBH
To: NYCOMED GERMANY HOLDING GMBH
Reel/Frame 036201/0261 →
MERGER Recorded Jul 28, 2015
From: TAKEDA GMBH
To: NYCOMED ASSET MANAGEMENT GMBH
Reel/Frame 036193/0178 →
CHANGE OF NAME Recorded Mar 26, 2013
From: NYCOMED GMBH
To: TAKEDA GMBH
Reel/Frame 030091/0737 →
CHANGE OF NAME Recorded Sep 4, 2007
From: ALTANA PHARMA AG
To: NYCOMED GMBH
Reel/Frame 019783/0625 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2006
From: KLEY, HANS-PETER
To: ALTANA PHARMA AG
Reel/Frame 017743/0266 →